Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,473.56 pence per share.
- Treasury Shares Held: 120,383,000 shares following the transaction.
- Shares in Issue: 5,827,728,471 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 1,000,000 shares on October 31, 2005, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,473.56 pence per share.
- Confirm the updated total share count (5,827,728,471 in issue) against subsequent filings to track capital structure changes.
- Review the company's broader capital allocation strategy to understand the context of holding 120,383,000 shares in Treasury.